Myriad Genetics, Inc. Reports Results for Second Quarter of Fiscal 2009

58% Product Revenue Growth and $0.43 EPS Highlight Quarter

Myriad Genetics, Inc. (NasdaqGS:MYGN) today reported financial results for the second quarter of fiscal 2009 and the six months ended December 31, 2008.

For the second quarter of fiscal 2009, the Company recorded a net profit of $21.2 million, or $0.46 basic earnings per share ($0.43 diluted earnings per share), compared to a net loss of $5.1 million and loss per share of $0.11 in the same quarter of the prior year. A major contributor to the Company's profitable quarter was its molecular diagnostics business, which increased its gross profit margin to 87% and its net operating margin to 51%, an improvement over the 86% gross profit margin and 39% net operating margin for the same three-month period in the prior year.

OPKO Receives FDA 510(k) Clearance for Spectral OCT SLO Combination Imaging System

OPKO Health, Inc. (NYSE Alternext US: OPK) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to begin marketing in the United States its Spectral OCT SLO Combination Imaging System. Currently marketed internationally by the Company’s subsidiary, OPKO Instrumentation, LLC, the Spectral OCT SLO is the product of more than a decade of innovation in the field of combination imaging. High-resolution images are produced with inner retinal choroid and vitreous detail that allow for improved monitoring of ophthalmic disease progression or regression.

AspenBio Pharma Reports Preliminary Results of AppyScore(TM) Clinical Study

Company to Host Conference Call to Discuss Results on January 22 at 4:30 PM ET

AspenBio Pharma, Inc. (NasdaqCM:APPY ), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for humans and animals, reported initial preliminary data from its Food and Drug Administration ("FDA") clinical trial for AppyScore(TM), the world's first blood-based test as an aid in the diagnosis of human appendicitis and an update on planned steps for pursuing FDA market authorization in the U.S.

Although data analysis is ongoing, the preliminary results demonstrate the relationship between AppyScore and the risk of pathologically proven appendicitis in patients with acute abdominal pain.

IRIS International Announces Preliminary Fourth Quarter and Full Year 2008 Operating Results

IRIS INTERNATIONAL, INC. (NASDAQ: IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced selected preliminary, unaudited results for the fourth quarter and year ended December 31, 2008.

Based on the Company’s preliminary results, total revenue for the fourth quarter is expected to be a record $26.7 million and a record $95.5 million for the full year. This represents an increase of 13% from revenue of $84.3 million in 2007, and is in line with the Company’s earlier stated guidance.